Aidoc’s latest $150 million Series E round, led by Goldman Sachs Alternatives’ Growth Equity arm and joined by General Catalyst, SoftBank Vision Fund 2 and Nvidia’s NVentures, pushes the company’s cumulative financing past the half‑billion‑dollar mark in under a year. The influx of capital validates the accelerating demand for enterprise‑scale clinical AI and underscores the confidence of late‑stage investors in Aidoc’s ability to deliver measurable operational and financial returns across large health systems.
The proceeds will be earmarked for scaling Aidoc’s CARE (Clinical AI Reasoning Engine) foundation model, broadening its FDA‑cleared portfolio to cover the full spectrum of acute and chronic conditions detectable on CT and X‑ray, and expanding the aiOS enterprise platform that embeds AI directly into clinical workflows. Recent moves into oncology and cardiovascular AI, together with the February 2025 clearance for the CADt rib‑fracture triage tool, position the firm to capture higher‑value use cases while addressing the growing pressure on radiology and cardiology departments worldwide. For MENA health systems grappling with physician shortages and rising imaging volumes, Aidoc’s end‑to‑end solution offers a pathway to reduce diagnostic latency, improve throughput, and generate tangible cost savings.
From a regional perspective, the round highlights a growing alignment between global venture capital and MENA sovereign investors seeking to catalyze digital health transformation. Sovereign wealth funds such as Mubadala, ADQ and the Public Investment Fund have earmarked substantial allocations for AI‑enabled healthcare infrastructure, viewing companies like Aidoc as critical partners in building resilient, data‑driven care networks. Successful deployment will hinge on harmonizing data‑governance standards, fostering local talent pipelines, and integrating Aidoc’s platform with national health‑information exchanges—steps that, if executed, could unlock significant efficiency gains and position the MENA region as a leader in scalable clinical AI adoption.
